Industry Focus
Healthcare: Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:21:49
- Mais informações
Informações:
Sinopse
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
